About Aradigm
Aradigm was a Healthcare company based in Hayward (United States) founded in 1991. It develops innovative technologies for inhalable therapies targeting respiratory diseases. It operates on a B2B model. The company has 23 employees. The company is recorded as dissolved. Its focus areas include Biotechnology, Respiratory Therapies and Inhalable Technologies. Its legal entity is Aradigm Corp. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Aradigm, established in 1991, excels in providing healthcare solutions, advancing biotech innovations, respiratory therapies, and inhalable technologies. Develops innovative technologies for inhalable therapies targeting respiratory diseases. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
- Headquarters Hayward, United States
- Employees 23
- SectorsHealthcare
- Website aradigm.com
- Legal Name Aradigm Corp
- Latest Funding Round$435.7K (USD), Grant
Aug 2017
- InvestorsNovo Nordisk
& 9 more
- Employee Count23
Funding Insights of Aradigm
- Total Rounds 16
- Last Round Grant — $435,698
- First Round $12M
(Apr 1998)
- Investors Count 10
Latest 10 of 16 funding rounds of Aradigm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2017 | $435,698 | Grant | – | – | |
| May 2016 | $23M | Post-IPO | – | – | – |
| Aug 2013 | $260,000 | Grant | – | – | |
| Aug 2013 | $236,178 | Grant | – | – | |
| Aug 2013 | $278,000 | Grant | – | – | |
| May 2013 | $41.41M | Post-IPO | – | – | – |
| Dec 2012 | $6M | Post-IPO | – | – | – |
| Jul 2011 | $4.75M | Post-IPO | – | – | |
| Jun 2010 | $4.11M | Post-IPO | – | – | – |
| Nov 2003 | $13.5M | Post-IPO | – | – | – |
10 investors in total: 10 institutional.
Investors in Aradigm
Aradigm has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Novo Nordisk, HHS and First Eagle Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Growth equity investments are made in lower middle market companies. | 1995 | camdenpartners.com | Owings Mills, United States | |
| castlecreek.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Research on heart, lung, blood, and sleep disorders is conducted. | nhlbi.nih.gov | Bethesda, United States | ||
| niaid.nih.gov | ||||
Diversified investment management services are provided to global clients. | 1864 | firsteagle.com | New York, United States | |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. | 1923 | novonordisk.com | Bagsvaerd, Denmark | |
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
Research-driven investment firm focused on global health care and bioscience sectors. | 1993 | oraclepartners.com | Stamford, United States |
Investor details for Aradigm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aradigm
8 people are tracked at Aradigm (7 in board & advisors, 1 in team); the tracked headcount is 23.
| Name | Role | Group |
|---|---|---|
Adam Wanner | Scientific Advisor | Board & advisors |
Stephen J. Farr | Scientific Advisor | Board & advisors |
Frederick Hudson | Director | Board & advisors |
Ed Gordon | Director | Board & advisors |
Theresa Matkovits | Director | Board & advisors |
Virgil D. Thompson | Chairman | Board & advisors |
Tunde Otulana | Scientific Advisor | Board & advisors |
John Siebert | Executive Chairman | Team |
Complete people profiles for Aradigm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aradigm
3 dated milestones of Aradigm across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Aradigm is founded.
- Funding First funding round of $12.0M.
- Funding Latest funding round, Grant, of $436K.
Competitors of Aradigm
Aradigm has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Aradigm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aradigm
Websites that share an audience with Aradigm (aradigm.com).
Websites whose visitors overlap most with Aradigm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mercatormed.com | 100% | 2.7K | #7,691,051 | View details | |
| iflo.com | 100% | 6.5K | #1,861,789 | View details | |
| anthera.com | 100% | View details | |||
| antarespharma.com | 97% | View details | |||
| argostherapeutics.com | 97% | View details |
Top companies in Microbiome Therapeutics
3 companies that operate in the same segment as Aradigm (Microbiome Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | 55 | ||
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | 12 | ||
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aradigm
Complete news archive for Aradigm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aradigm
Aradigm was founded in 1991 and raised its 1st funding round 7 years after it was founded.
Aradigm is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Aradigm has 23 employees.
Aradigm, established in 1991, excels in providing healthcare solutions, advancing biotech innovations, respiratory therapies, and inhalable technologies. Develops innovative technologies for inhalable therapies targeting respiratory diseases. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
Aradigm's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Aradigm has 10 investors. Key investors include Novo Nordisk, HHS, First Eagle Investments, GSK, and National Heart, Lung, and Blood Institute.
Aradigm operates through Aradigm Corp.